Biorevert Presents a Novel Target for Overcoming KRAS Inhibitor Resistance at AACR 2025 and Launches MObyDiCK Platform Service
- Biorevert identified TFF3 as a new target to overcome KRAS inhibitor resistance
- Biorevert launches a free trial of its systems biology-based target identification platform service (MObyDiCK)
Daejeon, South Korea/ April 21, 2025 – Biorevert Inc. (Choong-Hwan Lee, CEO) announced that they will present one of their latest research findings, a novel target to overcome resistance to KRAS inhibitors in non-small cell lung cancer (NSCLC), at the American Association for Cancer Research (AACR) Annual Meeting 2025.
During the poster presentation (#3706), Biorevert will introduce TFF3 as a new target identified using its proprietary asset, MObyDiCK platform (Mechanistic target Optimization by Discovering and Controlling networK) which is a systems biology-based drug discovery platform. In comparison to various deep learning-based approaches, MObyDiCK identifies a potential target with a greater mechanistic interpretability by prioritizing a list of functionally relevant targets. TFF3 was shown to form a positive feedback loop with SLPI, contributing to drug tolerance. Inhibition of TFF3 via a small-molecule inhibitor, AMPC, significantly enhanced sotorasib responses in KRAS G12C-mutant cells.
To revolutionize and accelerate systems biology-driven target discovery, Biorevert is officially launching MObyDiCK service, offering free access for all researchers and institutions to upload their datasets and explore mechanistically defined drug targets based on the uploaded datasets through the platform.
A Biorevert representative said that “Resistance to KRAS inhibitors remains a major clinical challenge. MObyDiCK platform is one and only kind of platform that uses a transformative and innovative approach by integrating single-cell transcriptomics and systems biology to identify actionable therapeutic targets. We are excited to share our results at AACR 2025 and look forward to be connected with various global companies and research institutions for potential partnerships and collaboration.”
ABOUT BIOREVERT
Biorevert is a university spin-out company with first-in-class target pipelines and innovative target discovery platform based on 25+ years of scientific research. Biorevert have two business models. First is to provide target discovery services to their potential customers with their AI- and systems biology-based target discovery MObyDiCK platform that can identify novel first-in-class target with its mechanism of action. Second, they also have various first-in-class pipelines to develop reversion therapy by reprogramming cancer cells into normal functioning cells without inducing normal cell death.
For further information, please visit www.biorevert.com
Try the platform: https://mobydick.biorevert.com
Contact: mobydick@biorevert.com
바이오리버트, AACR 2025서 KRAS 저항성 극복을 위한 신약 타겟 제시… MObyDiCK 플랫폼 전격 공개
- KRAS 저해제 저항성 극복을 위한 신규 타겟으로 TFF3 제시
- 시스템생물학 기반 신약타겟 발굴 플랫폼 MObyDiCK 체험형 버전 공개
대전 / 2025년 4월 21일 –바이오리버트 주식회사(대표 이충환)는 오는 미국암연구학회 연례학술대회(AACR 2025)에서 KRAS 변이 비소세포폐암(NSCLC) 환자의 치료 저항성을 극복하기 위한 신약 타겟 발굴 연구 성과를 발표한다고 밝혔다.
이번 포스터 발표(#3706)는 바이오리버트가 자체 개발한 시스템생물학 기반 신약타겟 발굴 플랫폼 ‘MObyDiCK’을 활용하여 진행된 연구로, 기존의 딥러닝 기반 방법보다 기전적 정밀성이 뛰어난 타겟 후보 유전자 TFF3를 도출한 점에서 주목을 받고 있다. 해당 유전자는 SLPI와의 피드백 회로를 통해 KRAS 저항성 획득에 관여하며, TFF3 억제제(AMPC) 처리 시 KRAS 억제제(소토라십)의 반응성을 유의미하게 향상시키는 것으로 확인되었다.
이번 발표를 기점으로 바이오리버트는 MObyDiCK 플랫폼의 서비스를 공식 출시하며, 전 세계 연구자와 기관이 데이터를 업로드하고 타겟을 탐색할 수 있는 체험형 버전을 무상으로 제공할 예정이다.
바이오리버트는 “KRAS 저항성 극복은 폐암 치료의 큰 도전 과제이며, MObyDiCK은 복잡한 단일세포 전사체 데이터를 활용하여 새로운 해결책을 제시할 수 있는 혁신 플랫폼”이라며 “이번 AACR 2025 발표를 통해 글로벌 연구 커뮤니티와의 협력을 기대한다”고 밝혔다.
플랫폼 체험: https://mobydick.biorevert.com
문의: mobydick@biorevert.com
Biorevert Presents a Novel Target for Overcoming KRAS Inhibitor Resistance at AACR 2025 and Launches MObyDiCK Platform Service
- Biorevert identified TFF3 as a new target to overcome KRAS inhibitor resistance
- Biorevert launches a free trial of its systems biology-based target identification platform service (MObyDiCK)
Daejeon, South Korea/ April 21, 2025 – Biorevert Inc. (Choong-Hwan Lee, CEO) announced that they will present one of their latest research findings, a novel target to overcome resistance to KRAS inhibitors in non-small cell lung cancer (NSCLC), at the American Association for Cancer Research (AACR) Annual Meeting 2025.
During the poster presentation (#3706), Biorevert will introduce TFF3 as a new target identified using its proprietary asset, MObyDiCK platform (Mechanistic target Optimization by Discovering and Controlling networK) which is a systems biology-based drug discovery platform. In comparison to various deep learning-based approaches, MObyDiCK identifies a potential target with a greater mechanistic interpretability by prioritizing a list of functionally relevant targets. TFF3 was shown to form a positive feedback loop with SLPI, contributing to drug tolerance. Inhibition of TFF3 via a small-molecule inhibitor, AMPC, significantly enhanced sotorasib responses in KRAS G12C-mutant cells.
To revolutionize and accelerate systems biology-driven target discovery, Biorevert is officially launching MObyDiCK service, offering free access for all researchers and institutions to upload their datasets and explore mechanistically defined drug targets based on the uploaded datasets through the platform.
A Biorevert representative said that “Resistance to KRAS inhibitors remains a major clinical challenge. MObyDiCK platform is one and only kind of platform that uses a transformative and innovative approach by integrating single-cell transcriptomics and systems biology to identify actionable therapeutic targets. We are excited to share our results at AACR 2025 and look forward to be connected with various global companies and research institutions for potential partnerships and collaboration.”
ABOUT BIOREVERT
Biorevert is a university spin-out company with first-in-class target pipelines and innovative target discovery platform based on 25+ years of scientific research. Biorevert have two business models. First is to provide target discovery services to their potential customers with their AI- and systems biology-based target discovery MObyDiCK platform that can identify novel first-in-class target with its mechanism of action. Second, they also have various first-in-class pipelines to develop reversion therapy by reprogramming cancer cells into normal functioning cells without inducing normal cell death.
For further information, please visit www.biorevert.com
Try the platform: https://mobydick.biorevert.com
Contact: mobydick@biorevert.com
바이오리버트, AACR 2025서 KRAS 저항성 극복을 위한 신약 타겟 제시… MObyDiCK 플랫폼 전격 공개
- KRAS 저해제 저항성 극복을 위한 신규 타겟으로 TFF3 제시
- 시스템생물학 기반 신약타겟 발굴 플랫폼 MObyDiCK 체험형 버전 공개
대전 / 2025년 4월 21일 –바이오리버트 주식회사(대표 이충환)는 오는 미국암연구학회 연례학술대회(AACR 2025)에서 KRAS 변이 비소세포폐암(NSCLC) 환자의 치료 저항성을 극복하기 위한 신약 타겟 발굴 연구 성과를 발표한다고 밝혔다.
이번 포스터 발표(#3706)는 바이오리버트가 자체 개발한 시스템생물학 기반 신약타겟 발굴 플랫폼 ‘MObyDiCK’을 활용하여 진행된 연구로, 기존의 딥러닝 기반 방법보다 기전적 정밀성이 뛰어난 타겟 후보 유전자 TFF3를 도출한 점에서 주목을 받고 있다. 해당 유전자는 SLPI와의 피드백 회로를 통해 KRAS 저항성 획득에 관여하며, TFF3 억제제(AMPC) 처리 시 KRAS 억제제(소토라십)의 반응성을 유의미하게 향상시키는 것으로 확인되었다.
이번 발표를 기점으로 바이오리버트는 MObyDiCK 플랫폼의 서비스를 공식 출시하며, 전 세계 연구자와 기관이 데이터를 업로드하고 타겟을 탐색할 수 있는 체험형 버전을 무상으로 제공할 예정이다.
바이오리버트는 “KRAS 저항성 극복은 폐암 치료의 큰 도전 과제이며, MObyDiCK은 복잡한 단일세포 전사체 데이터를 활용하여 새로운 해결책을 제시할 수 있는 혁신 플랫폼”이라며 “이번 AACR 2025 발표를 통해 글로벌 연구 커뮤니티와의 협력을 기대한다”고 밝혔다.
플랫폼 체험: https://mobydick.biorevert.com
문의: mobydick@biorevert.com